Low-dose formoterol Turbuhaler® (Oxis®) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.)

Respiratory Medicine

Volumn 92, Issue 8, 1998, Pages 1040-1045

  Ekstrom T ^a   Ringdal, N ^b   Sobradillo, V ^c   Runnerstrom E ^e   Soliman, S ^d  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b Molde Indremedicinske Kontor   (Norway)

^c HOSPITAL DE CRUCES   (Spain)

^d ASTRAZENECA R AND D   (Sweden)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; FORMOTEROL; TERBUTALINE; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL;

EID: 0031671194     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90352-3     Document Type: Article

References (21)

1. British Thoracic Society. Guidelines and self management of asthma in adults. Thorax 1997; 52 (Suppl. 1): S2-S8.
2. National Heart and Lung and Blood Institute. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Heart Lung and Blood Institute, 1995; 1-48.
3. Ida H. Comparison of the action of BD40a and some other β-adrenoceptor stimulants on the isolated trachea and atria of the guinea-pig. Arzneim-Forsch 1976; 26: 839-842.
4. 2-agonist for inhalation twice daily, compared with salbutamol in treatment of asthma. Thorax 1990; 45: 259-261.
5. 2-agonist, in chronic obstructive airway disease. Lung 1990; (Suppl. 40): 83-89.
6. Arvidsson P, Larsson S, Löfdahl CG, Melander B, Wåhlander L, Svedmyr N. Formoterol, a new long-acting bronchodilator for inhalation. Eur Respir J 1989; 2: 325-330.
7. Ringdal N, Derom E, Pauwels R. Onset of action of single doses of formoterol inhaled via Turbuhaler® in mild to moderate asthma. Eur Resp J 1995; 8 (Suppl. 19): 68s.
8. Schreurs AJM, Sinninghe-Damste HEJ, de Graaff CS, Greefhorst APM. A dose-response study with formoterol Turbuhaler® as maintenance therapy in asthmatic patients. Eur Resp J 1996; 9: 1678-1683.
9. Ekström T, Ringdal N, Tukiainen P. Formoterol Turbuhaler® 12 μg b.i.d. improves lung functions in asthmatic patients compared with terbutaline and placebo. Eur Resp J 1995; 8 (Suppl. 19): 157s.
10. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. 1987; 136: 225-243.
11. Kesten S, Chapman KR, Broder I, Cartier A et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992; 69: 415-420.
12. Stålenheim G, Wegener T, Grettve L, Lundback et al. Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease. Respiration 1994; 61: 305-309.
13. Steffensen I, Faurschou P, Riska H, Rostrup J, Wegener T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled, comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy 1995; 50: 657-663.
14. Molen van der T, Postma DS, Turner MO et al. Effects of the long-acting β-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1996; 52: 535-539.
15. Nathan R, Seltzer JM, Kemp JP, Chevinsky P. Safety of Salmeterol in maintenance treatment of asthma. Ann Allergy, Asthma Immunol 1995; 75: 43-48.
16. Boulet LP, Laviolette M, Boucher S, Knight A et al. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild to moderate asthma: a Canadian Multicenter study. J Allergy Clin Immunol 1997; 99: 13-21.
17. 2-agonists in the treatment of asthma? Chest 1995; 107: 1116-1124.
18. 2-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
19. 2 agonists. Thorax 1996; 51: 1051-1056.
20. Borgström L, Derom E, Ståhl E, Wåhlin Boll E, Pauwels R. Inhaler influences lung deposition and bronchodilating effects of terbutaline. Am Respir Crit Care Med 1996; 153: 1636-1640.
21. Carlsson LG, Arweström E, Friberg K, Lundhe H, Robertsson M, Löfdah LG. Half the dose of salbutamol required via Turbuhaler compared with Diskhaler for the same bronchodilating effect. Eur Respir J 1995; 8 (Suppl. 19): 201s.